Novadel Pharma Inc. (fka NVDL)

[Tstorm]

HUGE NVDL DD here : SHARE STRUCTURE
10 Million Float,
134 Million O/S
124 Million Held Inside

INSIDERS HOLDINGS WOWSER >> The 61,809,543 (NVDL) shares of Common Stock beneficially owned by the Reporting Persons represent 38.1% of the issued and outstanding shares of NVDL Common Stock based on 134,890,615 shares of Common Stock outstanding as set forth by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC. Of such 61,809,543 NVDL shares, 29,995,693, or 19.5%, are beneficially owned by Investments II; 193,233, or .1%, are beneficially owned by Advisors Fund; 30,188,926, or 19.6%, are beneficially owned by Associates II; 31,620,617, or 22.1 beneficially owned by each of Investments III and Associates III; and 61,809,543, or 38.1%, are beneficially owned by each of Moorin and Schreiber."

(..FOR MORE THAN 3 YEARS NOT A SINGLE SHARE SOLD BY ANY INSIDERS HERE, NOT 1 SHARE SOLD BY THEM NOW OR FOR MORE THAN 3 YEARS.
THEY KNOW OR KNEW THAT THE SHARE PRICE WOULD EVENUTALLY GO A LOT HIGHER.
JUST FOLLOW WHAT THE INSIDERS OF ANY STOCK ARE DOING, THAT IS JUST COMMON SENSE.)

2 HUGE PATENTED FDA APPROVED PRODUCTS

NitroMist? or ZolpiMist? intellectual property or licenses

http://www.novadel.com/pipeline/nitromist.htm

http://www.novadel.com/pipeline/zolpimist.htm

NovaDel has two marketed products that have been approved by the FDA: NitroMist? for the treatment of angina, and ZolpiMist? for the treatment of insomnia.

During the twelve months of 2012, the Company earned royalties from the license of NitroMist and ZolpiMist in the amount of $471,000. The Company also received $200,000 from the sale of NitroMist rights outside the US, Canada and Mexico. Also included in revenue is the recognition of previously received payments under various license agreements

HUGE NEWS RELEASED AUGUST 13/2013
Selling Majority of Assets for $400,000 plus 50,000,000 Shares of SUDA LTD. with an Option for 10,000,000 more at .05 Per Share

http://finance.yahoo.com/news/novadel-announces-stockholder-approval-sale-215500171.html

That's a $2,400,000 - $3,400,000 Deal which our TOP RATE CEO plans to eliminate Liabilites.

Steven B. Ratoff
President & Chief Executive Officer
Senior VP and CFO of the Pharmaceutical Group at Bristol-Myers Squibb. Mr. Ratoff brings extensive credentials to the Company from his distinguished career in the pharmaceutical and consumer goods industries.